Intelligence · Clinical Development
Pipeline search results
Programs matching “lenalidomide” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 18 pipeline programs matching "lenalidomide" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
68284528MMY3002
Janssen-Cilag International N.V.
Relapsed and Lenalidomide-Refractory Multiple Myeloma
1 trial -
CA088-1007
Celgene Europe Limited
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
1 trial -
Lenalidomide
Celgene Europe Limited
B-cell Chronic Lymphocytic Leukemia
1 trial -
MyelomaXIV
Takeda
Multiple Myeloma
1 trial -
2021-SR-545
The First People's Hospital of Lianyungang
Lymphoma, Large B-Cell, Diffuse
1 trial -
EAE 115
Wuhan Createrna Science and Technology Co., Ltd
Multiple myeloma patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor"
1 trial -
Lenalidomide
Takeda
Myeloma, Multiple
1 trial -
Lenalidomide
United Therapeutics Europe Ltd
Recurrent Mantle Cell Lymphoma
1 trial -
Lenalidomide
The First People's Hospital of Lianyungang
PTCL, NOS
1 trial -
Lenalidomide [Leavdo®]
Hospital Authority, Hong Kong
Antibiotics-unresponsive MALT Lymphoma
1 trial -
Lenalidomide and Gemcitabine (Dose level 11)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T-cell Lymphomas (PTCL)
1 trial -
Lenalidomide combined with G-CHOP (LO CHOP)
The First People's Hospital of Lianyungang
DLBCL - Diffuse Large B Cell Lymphoma
1 trial -
Zanubrutinib+Rituximab+Lenalidomide
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial -
lenalidomide combined with rituximab
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial -
Lenalidomide (CC-5013)
BRIGHT MINDS BIOSCIENCES INC.
Advanced Solid Tumors
1 trial -
Lenalidomide or Pomalidomide
ONCOLYTICS BIOTECH INC
Multiple Myeloma
1 trial -
K9520
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
Lenalidomide
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.